Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development[J]. Annu Rev Pathol, 2006, 1: 119-150.
[2]
Koyama H, Kobayashi N, Harada M, et al. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment[J]. Am J Pathol, 2008, 172(1): 179-193.
[3]
Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers[J]. Proc Natl Acad Sci USA, 1994, 91(12): 5657-5661.
[4]
Pineiro-Sanchez ML, Goldstein LA, Dodt J, et al. Identification of the 170 kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease[J]. J Biol Chem, 1997, 272(12): 7595-7601.
[5]
Santos AM, Jung J, Aziz N, et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice[J]. J Clin Invest, 2009, 119(12): 3613-3625.
[6]
Hayward SW. Preclinical assessment of fibroblast activation protein as a target for antitumor therapy[J]. Future Oncol, 2010, 6(3): 347-349.
[7]
Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α[J]. Science, 2010, 330(6005): 827-830.
[8]
Huber MA, Kraut N, Park JE, et al. Fibroblast activation protein: dirential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors[J]. J Invest Dermal, 2003, 120(2): 182-188.
[9]
Ramirez-Montagut T, Blachere NE, Sviderskaya EV, et al. FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor[J]. Oncogene, 2004, 23(32): 5435-5446.
[10]
Wuest T, Moosmayer D, Pfizenmaier K. Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein[J]. J Biotechnol, 2001, 92(2): 159-168.
[11]
Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanized monoclonal antibody: an early phase Ⅱ trial of sibrotuzumab in patients with metastatic colorectal cancer[J]. Onkologie. 2003, 26(1): 44-48.
[12]
Eager RM, Cunningham CC, Senzer NN, et al. Phase Ⅱ assessment of talabostat and cisplatin in second-line stage Ⅳ melanoma[J]. BMC Cancer, 2009, 9: 263.
[13]
Eager RM, Cunningham CC, Senzer NN, et al. Phase Ⅱ Trial of talabostat and docetaxel in advanced non-small cell lung cancer[J]. Clin Oncol, 2009, 21(6): 464-472.
[14]
Tsai TY, Yeh TK, Chen X, et al. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein[J]. J Med Chem, 2010, 53(18): 6572-6583.
[15]
Roskelley CD, Bissell MJ. The dominance of microenvironment in breast and ovarian cancer[J]. Cancer Biol, 2002, 12(2):97-104.
[16]
O’Brien P, O’Connor BF. Seprase:an overview of an important matrix serine protease[J].Biochim Biophys Acta, 2008, 1784(9): 1130-1145.
[17]
Goldstein LA,Ghersi G,Pi？eiro-Sánchez ML, et al. Molecular cloning of seprase:a serine integral membrane protease from human melanoma[J]. Biochim Biophys Acta, 1997, 1361(1): 11-19.
[18]
Cheng JD, Dunbrack RL Jr, Valianou M, et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model[J]. Cancer Res, 2002, 62(16): 4767-4772.
[19]
Aertgeerts K, Levin I, Shi L, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha[J]. J Biol Chem, 2005, 280(20): 19441-19444.
[20]
Aggarwal S, Brennen WN, Kole TP, et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites[J]. Biochemistry, 2008, 47(3): 1076-1086.
[21]
Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26):cell-surface proteases that activate cell signaling and are potential targets for cancer therapy[J]. Drug Resist Updat, 2005, 8(1-2): 51-58.
[22]
Cheng JD, Valianou M, Canutescu AA, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth[J]. Mol Cancer Ther, 2005, 4(3): 351-360.
[23]
Kelly T, Kechelava S, Rozypal TL, et al. Seprase, a membrane-bound protease, is overexpressed by invasiveand microinvasive ductal carcinoma cells of human breast cancers[J]. Mod Pathol, 1998, 11(9): 855-863.
[24]
Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis[J]. Hepatology, 1999, 29(6):1768-1778.
[25]
Tahtis K, Lee FT, Wheatley JM, et al. Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model[J]. Mol Cancer Ther, 2003, 2(8): 729-737.
[26]
Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer[J]. Clin Cancer Res, 2007, 13(6): 1736-1741.
[27]
Ariga N, Sato E, Ohuchi N, et al. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast[J]. Int J Cancer, 2001, 95(1): 67-72.
[28]
Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer[J]. Cancer Res, 2004, 64(8): 2712-2716.
[29]
Kloft C, Graefe EU, Tanswell P, et al. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients[J]. Invest New Drugs, 2004, 22(1): 39-52.
[30]
Liao D, Luo Y, Markowitz D, et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model[J]. PLoS One, 2009, 4(11): e7965.
[31]
Loeffler M, Krüger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake[J]. J Clin Invest, 2006, 116(7): 1955-1962.
[32]
Wen Y, Wang CT, Ma TT, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model[J]. Cancer Sci, 2010, 101(11): 2325-2332.
[33]
LeBeau AM, Brennen WN, Aggarwal S, et al. Targeting cancer stroma with a fibroblast activation protein-activated promelittin protoxin[J]. Mol Cancer Ther, 2009, 8(5): 1378-1386.
[34]
Lo PC, Chen J, Stefflova K, et al. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers[J]. J Med Chem, 2009, 52(2): 358-368.
[35]
Narra K, Mullins SR, Lee HO, et al. Phase Ⅱ trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer[J]. Cancer Biol Ther, 2007, 6(11): 1691-1699.
